CRC is a leading cause of cancer morbidity and mortality worldwide 1 . It is well established that genetic factors have an important role in the etiology of CRC 2,3 . Deleterious germline mutations in known susceptibility genes, notably APC (adenomatous polyposis coli), MLH1, MSH2, MSH6 and PMS2, confer high risk of CRC in hereditary cancer syndromes 3-6 . Most sporadic CRC cases, however, do not carry these high-penetrance mutations 3,4 . Since 2007, genome-wide association studies (GWAS) and subsequent fine-mapping analyses conducted in individuals of European descent have identified 21 lowpenetrance susceptibility loci associated with CRC risk 7-17 . Together, these common loci explain less than 10% of the familial relative risk of CRC in European populations 13, 14 . In a GWAS of 7,456 CRC cases and 11,671 controls conducted as part of the Asia Colorectal Cancer Consortium, we identified 3 new loci at 5q31.1 (near PITX1), 12p13.32
A r t i c l e s (near CCND2) and 20p12.3 (near HAO1) associated with CRC risk 18 . In addition, we discovered a new risk variant in the SMAD7 gene associated with CRC in East Asians 19 . Over the past 2 years, we have doubled the sample size in the Asia Colorectal Cancer Consortium and conducted a 4-stage GWAS, including 14,963 CRC cases and 31,945 controls, to identify additional susceptibility loci for CRC.
RESULTS

Study overview
We performed a fixed-effects meta-analysis to evaluate approximately 2.4 million genotyped or imputed SNPs on 22 autosomes from 5 GWAS (stage 1) conducted in China, Japan and South Korea, including in total 2,098 CRC cases and 6,172 cancer-free controls (Supplementary Tables 1 and 2) . There was little evidence of population stratification in these studies (Supplementary Figs. 1 and 2) , with genomic inflation factor λ < 1.04 in each of the five studies and the meta-analysis (λ 1,000 = 1.01). We selected 8, 539 SNPs showing evidence of association with CRC risk (P < 0.05) according to prespecified criteria (Online Methods). We also included the 31 riskassociated variants identified by previous GWAS [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , resulting in a total of 8,570 SNPs. Of these, 7,113 SNPs were successfully designed using Illumina Infinium assays as part of a large genotyping effort for multiple projects. Using this customized array, we genotyped an independent set of 3,632 CRC cases and 6,404 controls recruited in 3 studies (stage 2) conducted in China. After quality control exclusions, 6,899 SNPs remained for analysis in 3,519 cases and 6,275 controls. We evaluated associations between CRC risk and these SNPs in each study separately and then performed a fixed-effects meta-analysis to obtain summary estimates. Again, we observed little evidence of population stratification, either in the three studies individually (λ < 1.05) or combined (λ = 1.05, λ 1,000 = 1.01) ( Supplementary  Fig. 3) . In a meta-analysis of data from stages 1 and 2, we identified 559 SNPs showing evidence of association at P < 0.005. We then evaluated these SNPs using data from a large Japanese CRC GWAS (stage 3) with 2,814 CRC cases and 11,358 controls 20 . Thirty SNPs in 25 new loci were associated with CRC risk at P < 0.0001 in the meta-analysis of data from stages 1-3 and at P < 0.01 in the meta-analysis of stages 2 and 3. Of these SNPs, 29 were successfully genotyped in an independent sample of 6,532 CRC cases and 8,140 controls from 5 additional studies (stage 4) conducted in China, South Korea and Japan.
Newly identified risk-associated loci for CRC
In the meta-analysis of all data for the 29 SNPs from stages 1-4 with 14,963 CRC cases and 31,945 controls, signals from 10 SNPs, representing 6 new loci, showed convincing evidence of an association with CRC risk at the genome-wide significance level (P < 5 × 10 −8 ), including rs704017 at 10q22.3; rs11196172 at 10q25.2; rs174537, rs4246215, rs174550 and rs1535 at 11q12.2; rs10849432 at 12p13.31; rs12603526 at 17p13.3; and rs1800469 and rs2241714 at 19q13.2 (Table 1, Supplementary Fig. 4 and Supplementary Tables 3 and 4) . Associations of CRC risk with the top SNPs in each of the six loci were consistent across almost all studies, with no evidence of heterogeneity ( Fig. 1) . With the exception of the intergenic SNP rs10849432 at 12p13.31, the remaining nine newly identified risk-associated variants were located in exonic, promoter, 3′ UTR or intronic regions of known genes ( Table 1 ). The linkage disequilibrium (LD) blocks (r 2 > 0.5) tagged by rs704017 (10q22.3), rs174537 (11q12.2) and rs1800469 (19q13.2) each span multiple genes (Supplementary Table 5 ). The LD blocks tagged by rs11196172 (10q25.2) and rs12603526 (17p13.3) each lie within a single gene. The LD block tagged by rs10849432 (12p13.31) does not contain any known gene. Stratification analyses of the newly identified risk variants by tumor anatomical site (colon or rectum), population (Chinese, Korean or Japanese) and sex (male or female) did not identify any significant heterogeneity ( Supplementary Tables 6-8 ). In addition to the six newly identified loci, three additional regions showed association with CRC risk near genome-wide significance at 8q24.11 (rs6469656; P = 5.38 × 10 −8 ), 10q21.1 (rs4948317; P = 7.14 × 10 −8 ) and 10q24.2 (rs12412391; P = 7.41 × 10 −7 ). Results for all 29 SNPs across stages 1-4 are presented in Supplementary Table 3 .
We performed conditional analyses for SNPs located within a 1-Mb region centered on the index SNP in each of the six newly identified loci. 
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No second association signal was identified at P < 0.01 after adjusting for the respective index SNP (data not shown). Four SNPs at 11q12.2 and 2 SNPs at 19q13.2 showed association with CRC risk at P < 5 × 10 −8 , and we thus performed haplotype analysis for these 2 loci using genotype data available for 10,051 CRC cases and 14,415 controls (stages 2 and 4). Two common haplotypes were found in the 11q12.2 locus, accounting for more than 99% of the haplotypes constructed using the four highly correlated SNPs. The haplotype with all four risk-associated alleles (frequency = 0.574 in controls) was strongly associated with CRC risk (odds ratio (OR) = 1.40, 95% confidence interval (CI) = 1.29-1.51; P = 3.69 × 10 −16 ) ( Supplementary  Table 9 ). Similarly, we identified two common haplotypes at the 19q13.2 locus, accounting for more than 99% of the haplotypes constructed using the two highly correlated SNPs. The haplotype with the risk-associated allele at both SNPs (frequency = 0.485 in controls) was also associated with increased risk of CRC (OR = 1.16, 95% CI = 1.08-1.26; P = 1.18 × 10 −4 ) ( Supplementary Table 10 ). Overall, these analyses did not identify an independent signal in any of the six newly identified loci.
We examined potential SNP-SNP interactions between the 6 new risk-associated variants identified in this study (rs704017, rs11196172, rs174537, rs10849432, rs12603526 and rs1800469) and also between these 6 SNPs and the risk-associated variants in 25 previously reported loci ( Supplementary Table 11 ). Multiplicative interactions were found with suggestive evidence of association (P < 0.05) for seven pairs of SNPs. None of these interactions, however, remained statistically significant after correcting for multiple comparisons in 180 tests (adjusted P = 0.00028).
We evaluated associations of the 10 newly identified SNPs with CRC risk in individuals of European descent using data from 3 consortia, the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) 17 , the Colorectal Transdisciplinary (CORECT) Study and the Colon Cancer Family Registry (CCFR) 21 , with a total sample size of 16,984 CRC cases and 18,262 controls ( Supplementary Table 12 ). In a meta-analysis of data from these consortia, all ten SNPs showed association with CRC risk in the same direction as observed in East Asians ( Table 2) . Five SNPs in two loci (10q22.3 and 11q12.2) were associated with CRC risk at P < 0.008 (corrected for multiple comparisons of six loci). These associations in individuals of European descent, however, were weaker than in East Asians. Tests showed statistically significant evidence of heterogeneity for risk variants at 11q12.2 and 19q13.2 (P < 0.008). The frequency of the risk-associated allele was also considerably different in East Asians and individuals of European ancestry for SNPs in five loci ( Supplementary Table 13 ). For example, the minor allele (C) of rs12603526 is common in East Asians, 
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A r t i c l e s whereas the minor allele frequency (MAF) is <0.02 in individuals of European descent. These differences might in part reflect distinct patterns of LD between the index SNPs and causal SNPs in these two populations. As expected, LD patterns for most of the newly identified loci were considerably different in East Asians and individuals of European descent ( Supplementary Fig. 5 ). Large-scale fine-mapping of these loci will be helpful in identifying causal variants.
Putative functional variants and candidate genes
We evaluated and annotated putative functional variants and candidate genes in each of the six newly identified loci using data from the 1000 Genomes Project 22 , HapMap 2 (ref. 23 ), the Encyclopedia of DNA Elements (ENCODE) 24 , expression quantitative trait locus (eQTL) databases [25] [26] [27] [28] , the Catalogue of Somatic Mutations in Cancer (COSMIC) 29 , The Cancer Genome Atlas (TCGA) CRC project 30 , the Expression Atlas 31 , PubMed and Online Mendelian Inheritance in Man (OMIM) (Online Methods). We summarize the results below for each locus. At the 10q25.2 locus, rs11196172 is located in intron 4 of the TCF7L2 gene. This SNP and other correlated SNPs (r 2 > 0.5) fall within a region with strong enhancer activity and a DNase I hypersensitivity site annotated by ENCODE ( Supplementary Table 14 ), suggesting a potential functional role for these SNPs. We found that the riskassociated allele of rs11196172 was significantly associated with higher expression of the TCF7L2 gene (P = 0.003) in colon tumor tissue using TCGA data (Fig. 2) . The TCF7L2 gene encodes TCF7L2 (previously known as TCF4), which is a key transcription factor in the Wnt signaling pathway. Aberrant activation of Wnt signaling is found in more than 90% of CRCs 30 , and TCF7L2 is a known tumor suppressor in CRC. Loss of TCF7L2 function enhances CRC cell growth, whereas gain of function suppresses CRC cell growth 32, 33 . The TCF7L2 gene is one of the most frequently mutated genes in CRC, with estimated point mutation rates of approximately 8-12.5% (refs. 29,30) . Although TCF7L2 is the only gene in this locus ( Supplementary Fig. 4 ), we also found that the risk-associated allele of rs11196172 was significantly associated with higher expression of the VTI1A gene (P = 5.1 × 10 −4 ) in colon tumor tissue ( Fig. 2) . The VTI1A gene is located approximately 131 kb upstream of the TCF7L2 gene, and mRNA levels for these two genes are highly correlated in colon tumor tissue (r = 0.71; P < 0.0001). Recently, a recurrent gene fusion connecting the first three exons of VTI1A to the fourth exon of TCF7L2 was identified in approximately 3% of colorectal tumors 34 . It is possible that the VTI1A gene might also be involved in the association between rs11196172 and CRC risk.
At the 19q13.2 locus, we identified two perfectly correlated SNPs (rs1800469 and rs2241714; r 2 = 1) associated with CRC risk. Of these, rs1800469 has previously been investigated with respect to CRC risk in many small candidate gene association studies, with conflicting results 5 . We herein provide for the first time, to our knowledge, convincing evidence of association for rs1800469 through our GWAS analysis. SNP rs1800469 maps to the promoter of the TGFB1 gene, and rs2241714 is a nonsynonymous SNP that results in an amino acid substitution at residue 11 of the B9D2 protein. The A allele of rs1800469 has been related to higher transcriptional activity for the TGFB1 gene and higher circulating levels of the transforming growth factor (TGF)-β1 protein than the G allele 35 . Both rs1800469 and rs2241714 are in perfect LD with another nonsynonymous SNP, rs1800470, which causes a proline-to-leucine substitution at residue 10 of the TGF-β1 protein. Although the two nonsynonymous SNPs are predicted to be tolerated 36 or benign 37 , the Pro10 variant encoded by rs1800470 has also been associated with an increase in TGFB1 gene expression, TGF-β1 protein secretion and circulating levels of TGF-β1 protein [38] [39] [40] . Whereas rs2241714 is an eQTL for TGFB1, both rs1800469 and rs2241714 are also eQTLs for other genes in this locus ( Supplementary Table 15 ). In addition to these three SNPs, we suggest that many highly correlated SNPs located in the TGFB1 gene might potentially have regulatory functions ( Supplementary Table 14 ). The TGF-β1 protein is a member of the TGF-β signaling pathway. Somatic alterations of certain components in this pathway (TGFBR2, SMAD2, SMAD3 and SMAD4) are estimated to be present in almost half of CRCs 41 . High-penetrance germline mutations in the SMAD4 gene are known to cause juvenile polyposis, an autosomal dominant polyposis syndrome linked to a high risk of CRC 42 . Germline, allelespecific expression of the TGFBR1 gene has also been shown to contribute to increased risk of CRC 43 . Thus far, GWAS have identified at least six other independent SNPs that are located in or proximal to genes in the TGF-β signaling pathway (SMAD7, GREM1, BMP2, BMP4 and RHPN2) 9, 10, 13, 19 . Our finding of an association between a genetic variant in the TGFB1 gene and CRC risk adds further evidence for the critical role of this pathway in colorectal tumorigenesis.
At the 11q12.2 locus, the four perfectly correlated SNPs rs174537, rs4246215, rs174550 and rs1535 lie in intron 24 of MYRF, the 3′ UTR of FEN1, intron 7 of FADS1 and intron 1 of FADS2, respectively. Of these SNPs, rs4246215 is an eQTL for the FEN1 gene in normal colorectal tissue 44 and is predicted to affect microRNA (miRNA) binding site activity 45 . SNP rs174537 is an eQTL for the FADS1 and FADS2 genes in whole blood and other types of tissue ( Supplementary Table 15 ). Using data from TCGA, we identified a strong correlation of rs1535 
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A r t i c l e s genotypes with FADS2 gene expression (P = 1.4 × 10 −5 ) in colon tumor tissue ( Fig. 2) . These findings suggest that the potential functions of these SNPs might be mediated through their effects on their host genes. We also found that the FEN1, FADS1 and FADS2 genes are all highly expressed in colon tumor tissue compared with normal colon tissue ( Supplementary Table 16 ). The FEN1 gene encodes flap structure-specific endonuclease 1, a protein that is essential for DNA repair, replication and degradation and that has a critical role in maintaining genome stability and protecting against carcinogenesis 46 . FEN1 mutations have been found in several human cancers 47 . Mouse models with haploinsufficiency for Fen1 showed rapid progression of CRC and reduced survival 48 . Two other genes in this locus, FADS1 and FADS2, respectively encode delta-5 and delta-6 desaturases, which are key enzymes in the metabolism of polyunsaturated fatty acids. Of these proteins, delta-6 desaturase is responsible for the synthesis of arachidonic acid 49 , the precursor of prostaglandin E 2 (PGE 2 ), which is a key molecule mediating the effect of cyclooxygenase-2 in colorectal carcinogenesis 50 . Notably, SNPs in perfect LD with the risk-associated variants for CRC identified in this study are strongly associated with circulating arachidonic acid levels 49 . We have shown previously that high levels of the PGE 2 metabolite in urine, a marker of endogenous PGE 2 production, are strongly related to higher risk of CRC 51 .
Because the LD block of approximately 190 kb tagged by the four riskassociated variants covers many putatively functional SNPs that are located in the FEN1, FADS1 and FADS2 genes ( Supplementary Fig. 6 and Supplementary Table 14 ), it is difficult to pinpoint a single SNP or gene that might be responsible for the association with CRC risk in this locus. Nevertheless, our study provides evidence of a potentially important role for the FEN1, FADS1 and FADS2 genes in the etiology of CRC. At the 10q22.3 locus, rs704017 is located in intron 3 of the ZMIZ1-AS1 gene and resides in a strong enhancer region predicted using ENCODE data ( Supplementary Fig. 6 and Supplementary Table 14 ). It also maps to a DNase I hypersensitivity site identified in the Caco-2 CRC cell line. In addition to the ZMIZ1-AS1 gene, the LD block tagged by rs704017 also includes the ZMIZ1 gene, whose expression is downregulated in the Caco-2 and HT-29 CRC cell lines 31 . In line with these observations, we found in TCGA data that ZMIZ1 gene expression is lower in colon tumor tissue compared with normal colon tissue (P = 3.28 × 10 −6 ). In addition, somatic mutations in the ZMIZ1 gene have been reported in more than 2% of colon tumors 29 . Whereas ZMIZ1-AS1 is a miscellaneous RNA (miscRNA) gene with unknown function, the ZMIZ1 gene encodes the protein ZMIZ1, which regulates the activity of several transcription factors, including AR, SMAD3, SMAD4 and p53. It has been shown that ZMIZ1 might have a broader role in epithelial cancers, including CRC 52 . SNP rs704010, located in intron 1 of the ZMIZ1 gene, has been associated with breast cancer 53 . However, this SNP, which is in weak LD (r 2 = 0.09) with the risk-associated variant we identified for CRC, was not associated with CRC in this study (data not shown). Given the biological function of the ZMIZ1 gene, it is possible that this gene is involved in the association observed in this locus.
In the 12p13.31 locus, rs10849432 maps to an LD block of approximately 52 kb with no known genes. ENCODE data suggest that rs4764551 and rs4764552, perfectly correlated with rs10849432, might be located in a strong enhancer region ( Supplementary Table 14) . Notably, rs4764551 also maps to a DNase I hypersensitivity site in the HCT-116 CRC cell line and a binding site for the CTCF protein in the Caco-2 CRC cell line. Using data from TCGA, we showed that the closest genes to rs10849432 (CD9, PLEKHG6 and TNFRSF1A) all have downregulated expression in colon tumor tissue ( Supplementary   Table 16 ). The CD9 gene encodes the CD9 antigen, which participates in many cellular processes, including differentiation, adhesion and signal transduction. Notably, CD9 has a critical role in the suppression of cancer cell motility and metastasis 54 , and overexpression of the CD9 gene is associated with favorable prognosis for patients with CRC 55 . CD9 is also involved in suppressing Wnt signaling 56 . Although the function of the PLEKHG6 gene is less clear, somatic mutations in this gene were found in approximately 2% of colon tumors 29 . The protein encoded by TNFRSF1A is a major receptor for tumor necrosis factor (TNF)-α and is known to be involved in cytokine-induced senescence in cancer 57 . In addition to evidence for the three nearby genes, we also found that rs4764552 is an eQTL for the LTBR gene ( Supplementary  Table 15 ). The LTβR protein has an essential role in lymphoid organ formation and has also been linked to cancer 58 , including CRC 59 . On the basis of these data, we propose that the CD9 gene is the most likely candidate to explain the association identified in this locus. However, potential roles for other genes cannot be excluded.
At the 17p13.3 locus, rs12603526 lies in intron 1 of the NXN gene, in a region covering several regulatory elements, including a DNase I hypersensitivity site, a strong enhancer region and a site with an effect on regulatory motifs as annotated by ENCODE ( Supplementary  Table 14 ). NXN gene expression was lower in the colon tumor tissue samples included in TCGA (P = 2.83 × 10 −5 ). Nucleoredoxin, encoded by the NXN gene, has functions related to cell growth and differentiation 60 . Overexpression of the NXN gene has been found to suppress the Wnt signaling pathway, and nucleoredoxin dysfunction might cause activation of the transcription factor TCF (T cell factor), accelerated cell proliferation and enhancement of oncogenicity 61 . Further research is needed to determine the causal variant and biological mechanism for the association at this locus.
Previously reported CRC-associated loci in East Asians
We evaluated association evidence for 31 SNPs in 25 established CRC susceptibility loci 7-20 by analyzing data from stages 1-3 and our previous GWAS 18, 19 with a total sample size of up to 11,934 CRC cases and 28,282 controls ( Table 3 and Supplementary Table 17 ). We found further evidence to support the associations of the four loci identified previously in our GWAS conducted among East Asians (P = 1.40 × 10 −10 to 3.05 × 10 −15 ). Of the 23 SNPs in the 18 susceptibility loci previously identified by GWAS of individuals of European descent, 20 showed association with CRC risk at P < 0.05 in East Asians in the same direction as reported in the original studies [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . These signals included 6 SNPs in 4 loci (1q41, 8q24.21, 10p14 and 18q21.1) with association at P < 5 × 10 −8 , 6 SNPs in 6 loci with association at P < 0.002 (significance level adjusted for multiple comparisons of 25 independent loci) and 8 SNPs in 8 additional loci with association at P < 0.05. Three SNPs in three loci were not associated with CRC risk (P > 0.05). Given that our study had a statistical power of >80% to identify an association with an OR of 1.05 at P = 0.05 for SNPs with a MAF of 0.20, it is unlikely that these three SNPs confer substantial risk of CRC in East Asian populations. In general, loci initially identified in individuals of European descent had smaller ORs in East Asians, with evidence of heterogeneity noted for three SNPs (P < 0.002). SNPs rs6691170 and rs16892766, identified by previous GWAS of individuals of European descent, are not polymorphic in East Asians, and SNP rs5934683 is located on the X chromosome. We did not have data to evaluate the associations of these three SNPs with CRC risk in this study.
Familial relative risk explained by CRC-associated loci
The six newly identified loci in this study explain approximately 2.1% of the familial relative risk of CRC in East Asians ( Supplementary Table 18 ).
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The variants, along with the four SNPs identified in our previous GWAS, explained approximately 4.3% of the familial relative risk of CRC in East Asians. An additional 3.4% of the familial relative risk in East Asians can be explained by 18 independent SNPs initially identified in studies conducted among individuals of European descent and confirmed in this study. On the basis of per-allele OR values derived 
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A r t i c l e s from previously published GWAS [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] and this study, we estimate that the SNPs in the 31 loci identified thus far explain approximately 9% of the familial relative risk of CRC in individuals of European descent ( Supplementary Table 19 ), a level slightly higher than the 7.7% explained in East Asians.
DISCUSSION
In the largest GWAS conducted thus far among East Asians, we identified six new genetic loci associated with CRC risk and provided suggestive evidence for three additional previously unreported loci. In addition, we replicated 22 previously reported CRC susceptibility loci. Of the six newly identified loci, two map to genes (TCF7L2 and TGFB1) that have established roles in colorectal tumorigenesis. The other four loci are located in or proximal to genes that are functionally important in transcription regulation (ZMIZ1), genome maintenance (FEN1), fatty acid metabolism (FADS1 and FADS2), cancer cell motility and metastasis (CD9), and cell growth and differentiation (NXN). Risk-associated variants at some loci fall within potential functional regions, and two are associated with the expression levels of the TCF7L2 and FADS2 genes. This study expands current understanding of the genetic basis of CRC risk and provides evidence for new genes and biological pathways that might be involved in colorectal tumorigenesis.
On the basis of a large twin study conducted in Sweden, Denmark and Finland 2 , the heritabilities estimated for CRC, breast cancer and prostate cancer were 35%, 27% and 42%, respectively. Thus far, more than 70 low-penetrance susceptibility loci have been identified in GWAS for breast cancer 62 or prostate cancer 63 , and these loci together explain approximately 14% and 30%, respectively, of the familial relative risk of these cancers in individuals of European descent. For CRC, however, only 31 low-penetrance susceptibility loci have been identified, explaining approximately 9% of the familial relative risk of CRC in individuals of European descent. Compared with GWAS of breast cancer and prostate cancer, studies conducted for CRC have been relatively small. Our study, in which we evaluated approximately 7,000 promising variants identified by GWAS in the replication stages, represents one of the largest efforts thus far to follow up genetic variants identified by GWAS. We identified six new loci, representing the largest number of new loci identified for CRC risk in a single study. Although multiple GWAS with sample sizes larger than the one in this study have been conducted among individuals of European descent 13, 14, 16 , we were still able to identify risk-associated variants with relatively large effect sizes. Our study further highlights the value of conducting GWAS in non-European populations to discover new susceptibility loci for CRC.
In summary, we have identified six new loci associated with CRC risk in this large GWAS conducted among East Asians. These new loci contain genes with established connections to colorectal tumorigenesis through major biological pathways such as Wnt and TGF-β signaling, as well as genes with important biological functions that have not yet been well linked to CRC. Our study considerably expands knowledge of the genetic landscape of CRC and provides direction for future studies to characterize the causal variants and functional mechanisms of these GWAS-identified loci. 
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METhODS
Methods and any associated references are available in the online version of the paper.
program. SNPs showing an association at P < 5 × 10 −8 in the combined analysis of all studies were considered genome-wide significant. We also performed stratified analyses for the top SNPs by tumor anatomical site (colon or rectum), population (Chinese, Korean or Japanese) and sex (male or female). We estimated heterogeneity across studies and subgroups with a Cochran's Q test 76 , with P for heterogeneity < 0.008 set as statistically significant when considering multiple comparisons of six independent loci. Independent signals in a locus were identified using stepwise logistic regression models conditioning on the top risk-associated variant we identified in each of the new loci using R software (see URLs). We estimated haplotype frequencies using Haploview (version 4.2) 77 (see URLs) and conducted haplotype association analysis for two loci (11q12.2 and 19q13.2) where two or more SNPs were identified using SAS Genetics v9.3 with logistic regression models. Pairwise SNP-SNP interactions between 6 top risk-associated variants in the newly identified loci with association P < 5 × 10 −8 and also between these 6 SNPs and the risk-associated variants in 25 previously reported loci were evaluated using the maximumlikelihood ratio test with inclusion of interaction terms in logistic regression models. Interactions with P < 0.00028 were considered statistically significant with adjustment for multiple comparisons of 180 tests.
The familial relative risk (λ) for the offspring of an affected individual due to a single locus was estimated using a log-additive model: λ = (pr 2 + q)/ (pr + q) 2 , where p is the frequency of the risk allele, q = 1−p is the frequency of the reference allele and r is the per-allele relative risk 78 . The proportion of the familial relative risk explained by this locus, assuming a multiplicative interaction between markers in the locus and other loci, was calculated as log (λ)/log (λ 0 ), where λ 0 is the overall familial relative risk. λ 0 is assigned to be 2.2 for CRC risk estimated from a meta-analysis 79 . Assuming that the risks associated with individual loci combine multiplicatively, the familial relative risks also multiply. Thus, the combined contribution of the familial relative risks from multiple loci is equal to
We generated forest plots and quantile-quantile plots using R software (see URLs). Regional association plots for SNPs in newly identified loci were generated using the website-based tool LocusZoom (version 1.1) 80 (see URLs). LD structure between SNPs was determined on the basis of data from 1000 Genomes Project Pilot 1 or HapMap 2 as provided by the website-based tool SNAP 81 (see URLs) and plotted using Haploview, SNAP and the UCSC Genome Browser (see URLs). LD blocks were defined using HapMap recombination rates and hotspots 23 . All genomic coordinates are based on NCBI Build 36.
To find putative functional variants for newly identified loci, we identified all SNPs in LD (r 2 > 0.5) with the risk-associated variants using data from the 1000 Genomes Project 22 and HapMap 2 (ref. 23) . We mapped the genomic locations of these SNPs to nonsynonymous sites, splice sites, promoters, near-Gene-3 regions, nearGene-5 regions, 3′ UTRs, 5′ UTRs, introns and intergenic regions. We evaluated the potential functional effect of nonsynonymous SNPs using the prediction algorithms SIFT 36 and PolyPhen-2 (ref. 37) (see URLs). We predicted the putative function of SNPs in promoters, nearGene-3 regions, nearGene-5 regions, 3′ UTRs and 5′ UTRs with the SNPinfo Web Server 45 (see URLs). We conducted analyses to evaluate the potential regulatory effect of SNPs in noncoding regions on transcription using the ENCODE tool HaploReg (v2) 82 and the UCSC Genome Browser (see URLs) on the basis of their location within regions of promoter or enhancer activity, DNase I hypersensitivity, local histone modification, proteins bound to these regulatory sites, cis-eQTL and transcription factor binding motifs. We obtained additional functional evidence for these SNPs from the published literature.
We identified all genes that localize to 1-Mb windows centered on the top risk-associated variants in our newly identified loci, including SNPs correlated (r 2 > 0.5) with the top risk variants. To determine whether these genes might explain the observed associations in these loci, we first examined genomewide cis-eQTL data in multiple tissues from four major eQTL databases: the Blood eQTL Browser 25 , the eQTL Browser 26 , the Genotype-Tissue Expression (GTEx) Project 27 and the Multiple Tissue Human Expression Resource (MuTHER) Project 28 . The significance threshold for these analyses was set to P < 0.008 to account for six tests. Somatic mutations of these genes were evaluated using data from COSMIC 29 (see URLs). Expression levels of these genes in CRC cell lines were assessed using data from the Expression Atlas 31 (see URLs). To correct for multiple comparisons of the 11 key genes, associations with P < 0.0045 were considered to be statistically significant. We searched the published literature for these genes with respect to CRC in PubMed and OMIM (see URLs). Expression analysis. We downloaded RNA sequencing (level 1) and SNP array (level 2) data for 364 colon adenocarcinoma and 18 normal colon tissue samples from TCGA 30 (see URLs). To quantify expression levels of candidate genes in the newly identified loci, we normalized gene expression levels using RPKM (reads per kilobase of exon per million mapped reads) values as previously described 83 . Expression differences between tumor and normal samples for each gene were evaluated on the basis of RPKM values with the Wilcoxon ranksum test. Associations between gene RPKM values and SNP genotypes were analyzed using a linear regression model including age and sex as covariates. We converted the RPKM value of a gene to log scale for analysis if it was not normally distributed. We considered P < 0.0045 to be statistically significant with adjustment for testing of the 11 key genes.
